![]() |
|
|
Vol. 289, Issue 2, 965-975, May 1999
Behavioral Pharmacology Laboratory, Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Abstract |
|---|
|
|
|---|
Effects of low (butorphanol, nalbuphine)-, intermediate (buprenorphine)-, and high (morphine, levorphanol)-efficacy µ opioids were examined in F344, Sprague-Dawley (SD), Long-Evans (LE), and Lewis rats using a tail withdrawal and a drug discrimination procedure. In the tail withdrawal procedure using low (50°C), intermediate (52°C), and high (56°C) water temperatures, morphine and levorphanol produced maximal effects in each of the strains and were most potent in F344 and least potent in Lewis. Similar differences across strains were obtained with buprenorphine, and at the high intensity, maximal effects were not obtained in Lewis. At the low intensity, butorphanol produced maximal effects in F344 and SD at relatively low doses, half-maximal effects in LE at very high doses, and no effect in Lewis. Nalbuphine produced near maximal effects in F344 and SD when tested with the low intensity and no effect in the LE and Lewis. Similar results were obtained at the intermediate intensity for these opioids, although the absolute level of antinociception was lower. These results indicate that there are profound differences to the antinociceptive effects of µ opioids across rat strains. The magnitude of these differences increased with higher stimulus intensities and when tested with lower efficacy opioids. In rats trained to discriminate morphine (3.0 or 5.6 mg/kg) from water, there were no consistent differences across rat strains to the effects of these µ opioids. Possible reasons for differences between the results obtained in the tail withdrawal and drug discrimination procedures are discussed.
| |
Introduction |
|---|
|
|
|---|
There
is an increasing interest in utilizing different strains of rats to
elucidate the underlying mechanisms mediating sensitivity (both the
potency and the effects obtained at a particular dose) to the effects
of opioids (Marley et al., 1992
). For example, differences in
sensitivity to the reinforcing effects of morphine, etonitazene, and
codeine across various strains of rats occasionally have been noted.
These studies generally show that Lewis self-administer more drug than
F344, which self-administer more drug than Wistar or Sprague-Dawley
(SD; Carroll et al., 1986
; Suzuki et al., 1988
, 1992
; Hyyatia and
Sinclair, 1993
; Sudakov et al., 1993
; Ambrosio et al., 1995
; Shoaib et
al., 1995
). In contrast, studies examining morphine-induced changes in
locomotor activity (Sudakov et al., 1993
), schedule-controlled
responding (Witkin and Goldberg, 1990
), and eating and drinking
(Gosnell and Krahn, 1993
) have generally found relatively small strain differences.
Similarly, studies have not revealed consistent and/or robust
differences to the antinociceptive effects of morphine between rat
strains (Sudakov et al., 1993
, 1996
; Vaccarino and Couret, 1995
;
Woolfolk and Holtzman, 1995
; Kamei et al., 1996
). For example, in a
radiant heat tail-flick procedure, Wistar, SD, Lewis, F344, and
Long-Evans (LE) rats all display maximal effects at the same dose of
morphine (Woolfolk and Holtzman, 1995
). In contrast, in a tail
withdrawal procedure, a small but replicable difference in
antinociception produced by a single dose of morphine has been noted
with F344 being more sensitive than Wistar (Sudakov et al., 1993
,
1996
). Because these studies typically use a high-efficacy µ opioid,
such as morphine, and one level of the nociceptive stimulus, the
generality of these findings has not been well established. Such issues
are of critical importance when examining the effects of opioids, as
the level of antinociception produced by any opioid is dependent on its
intrinsic efficacy and the intensity of the nociceptive stimulus
(O'Callaghan and Holtzman, 1975
; Morgan and Picker, 1996
; Morgan et
al., 1999
). It is well established, for example, that
high-efficacy µ opioids produce maximal effects in antinociceptive
assays using relatively low- and high-intensity nociceptive stimuli,
whereas the maximal effects produced by low-efficacy µ opioids
decrease with increases in the intensity of the nociceptive stimulus.
Moreover, in instances in which low-efficacy µ opioids fail to
produce maximal effects they antagonize the effects of high-efficacy µ opioids (Walker et al., 1993
; Butelman et al., 1995
; Morgan et al.,
1999
).
Similarly, when examining the discriminative stimulus effects of
opioids, parametric manipulations and using opioids with varying
degrees of efficacy are critically important. In general, high-efficacy µ opioids substitute for both low and high training doses of
morphine, whereas low-efficacy µ opioids substitute only for low
training doses of morphine (Young et al., 1992
; Picker et al., 1993
).
Although the discriminative stimulus effects of morphine and other µ opioids have been examined extensively in a number of rat strains, the
use of different training doses, routes of drug administration, and
tested opioids makes it extremely difficult to determine if differences
exist across strains. Moreover, F344 and Lewis rats, which typically
display relatively large differences to other effects of opioids, are
not commonly used in these procedures.
If there are differences in the underlying mechanisms mediating the
effects of opioids in different strains of rats, it would be most
apparent under extreme circumstances; that is, when relatively insensitive tasks are used (i.e., tasks that require a large proportion of receptors to be activated to produce a given effect) or when opioids
with lower efficacy are used (i.e., opioids that need to bind to a
large majority of the receptors to produce a given effect). The purpose
of the present study was to evaluate this hypothesis by examining the
effects of several µ opioids in an antinociception and a drug
discrimination procedure. Four strains of rats (F344, SD, LE, and
Lewis) commonly used in behavioral procedures were examined. To
determine the importance of task sensitivity, various intensities of
the nociceptive stimulus (water temperature) were examined in the warm
water tail withdrawal procedure, and a relatively low and high training
dose of morphine was examined in the drug discrimination procedure. The
role of the intrinsic efficacy was examined by using low (butorphanol,
nalbuphine)-, intermediate (buprenorphine)-, and high (morphine,
levorphanol)-efficacy µ opioids (Adams et al., 1990
; France and
Woods, 1990
; Paronis and Holtzman, 1992
; Young et al., 1992
; Picker et
al., 1993
; Morgan et al., 1999
).
| |
Materials and Methods |
|---|
|
|
|---|
Subjects. Experimentally naive rats were obtained from Charles River Suppliers (Raleigh, NC). Rats of the LE, SD, Lewis, and F344 strains were maintained at approximately their 80% free feeding body weight by restricting daily intake of Purina Rat Chow, had unlimited access to water, and were housed individually in a climate-controlled colony maintained on a 12-h light/dark cycle.
Apparatus. Antinociceptive tests were conducted with 40, 50, 52, and 56°C water, maintained at the particular temperature using hot water baths (Fisher Scientific, Inc., Fairlawn, NJ). Tail withdrawal latencies were measured using a hand-operated digital stopwatch with a time resolution of 0.01 s. Drug discrimination sessions were conducted in seven plastic and aluminum operant conditioning chambers: four chambers were 23 cm long, 19 cm high, and 20 cm wide and four chambers were 25 cm long, 31 cm high, and 25 cm wide. Each chamber was equipped with two 5-cm-long response levers located 9 cm from the chamber floor and either 1 or 3 cm from either wall, with either two or three stimulus lights located above them. When operated, a pellet dispenser delivered a 45-mg Noyes food pellet (P.J. Noyes, Co., Lancaster, NH) into a pellet trough that was centrally mounted between the two levers and approximately 1 cm above the chamber floor. House lights were centrally mounted on the ceiling 2.5 cm from the rear wall in four chambers and 1 cm below the ceiling on the front wall in four chambers. All chambers were equipped with an exhaust fan that supplied ventilation and white noise to mask extraneous sounds. Scheduling of experimental events and data collection were accomplished through the use of a microcomputer, using software and interfacing supplied by MED Associates, Inc. (St. Albans, VT).
Antinociception Testing. In this procedure, rats were gently restrained and approximately half of the distal portion of the tail placed in either 40, 50, 52, or 56°C water, and the latency to remove the tail was recorded using a hand-held stopwatch. An increase in the latency to remove the tail from the warm water was taken as a measure of antinociception with an upper cutoff time of 15 s. In one series of tests, trials with the 40°C water were conducted once in each rat, followed by two baseline latency scores for both the 50 and 52°C water. The order of warm water tests was counterbalanced across rats, with at least 3 min separating each trial. In a second series of tests, baseline trials were conducted with 40 and 56°C water.
After baseline tail withdrawal latencies were determined under these conditions, the testing procedure was initiated. For tests conducted with the 50 and 52°C water, 30 min after administration of the opioid, one test was conducted using one water temperature, and then 3 min later the other temperature was used, with the order of testing counterbalanced across rats. Three min later, the next injection was administered, and the cycle began again. Each successive dose increased the total opioid concentration by 0.25 or 0.5 log units. A similar procedure was used when tests were conducted with the 56°C water, with the exception that only one water temperature was used. For any given rat, no more than five tests were conducted with a minimum of 1 week separating tests. Each drug was tested in 7 to 10 rats.Drug Discrimination Training and Testing. Rats were initially trained to press either of two response levers for food delivery, with responding maintained by a fixed ratio (FR) 1 schedule. During preliminary sessions, the lever designated as correct varied from session to session, and over several sessions the ratio value on each lever was increased gradually until a FR20 schedule was in effect. Discrimination training began when the FR value on each lever was approximately 10 (FR10). During these training sessions, injections of the training drug (3.0 or 5.6 mg/kg morphine) or 1.0 ml/kg water were administered 30 min before the session. A random sequence was used to determine which injection was administered, with the restriction that the same injection was not given on more than two consecutive sessions and that the number of drug and water injections was approximately equal over a 30-session period. After injection of the training drug, responses on one lever were reinforced, whereas responses on the other lever were recorded but had no programmed consequences. After injection of water, the contingencies were reversed. For approximately half of the rats, the left lever was designated morphine-appropriate, and the right lever was designated water-appropriate. These conditions were reversed for the other rats. Sessions lasted 15 min and were conducted 5 days per week. Training continued until the mean percentage of injection-appropriate responding before delivery of the first reinforcer was equal to or greater than 80% over 10 consecutive sessions.
Once the discrimination criterion was met, substitution tests were initiated. These tests were typically conducted on Tuesdays and Fridays, whereas training sessions continued on Mondays, Wednesdays, and Thursdays. If discrimination performance was <80% injection-appropriate before the delivery of the first reinforcer on Monday or Thursday, the next scheduled test session was replaced with a training session. During all test sessions, the conditions were the same as during the training sessions, except that completion of the FR20 requirement on either lever was reinforced. Rats from all four strains were trained with the 3.0 mg/kg training dose. Based on the antinociception experiments, F344 and Lewis appeared the most and least sensitive to the effects of these opioids. Therefore, additional groups of rats (F344 and Lewis) were trained to discriminate 5.6 mg/kg morphine from saline. Because no differences were observed at this higher training dose, rats of the LE and SD strains were not trained with this dose. In addition, it was determined (data not shown) that rats could not be trained with 10.0 mg/kg morphine, as this dose completely suppressed responding and endangered the health of the animals. There were eight rats in each 3.0 mg/kg training dose group and 12 rats in each 5.6 mg/kg training dose group. Each drug was tested in five to eight rats, except morphine, which was tested in all rats.Data Analysis.
Tail withdrawal latencies (test latency) were
converted to percent antinociceptive effect using the following
equation:
|
Drugs. The following drugs were used: morphine sulfate, buprenorphine hydrochloride (both provided by the National Institute on Drug Abuse), butorphanol tartrate (generously supplied by Bristol-Meyers, Wallingford, CT), levorphanol tartrate, and nalbuphine hydrochloride (both purchased from Research Biochemicals Inc., Natick, MA). All drug doses are expressed in terms of the salts. All drugs were dissolved in distilled water and administered i.p. in an injection volume of 0.5 to 1.0 ml/kg.
| |
Results |
|---|
|
|
|---|
Tail Withdrawal Procedure. Baseline performance. When tested with the 40°C control water, all latencies were 15 s. Table 1 shows that the control withdrawal latencies varied as a function of stimulus intensity (F2,44 = 97.0, p < .05) but not as a function of rat strain. That is, average latencies for 50, 52, and 56°C water were 10.7, 7.4, and 3.9 s, respectively. However, there were no differences in baseline latency across rat strains for each of the temperatures.
|
Effects of opioids.
Fig. 1 shows
the effects of the high-efficacy µ opioids morphine and levorphanol
in the tail withdrawal procedure using 50, 52, and 56°C water. In
F344, SD, LE, and Lewis rats, morphine produced dose-dependent
increases in percent antinociceptive effects with maximal effects
(i.e., >80% antinociceptive effect) obtained at each of the water
temperatures. Based on ED50 values (Table 2), the potency of morphine decreased
with increases in the water temperature in F344, SD, and Lewis rats. At
the 52 and 56°C water temperatures, morphine was approximately 2.0- and 3.0-fold more potent in the F344 than the Lewis, respectively.
Although the absolute differences across strains were small, the mean
rank order of morphine's potency was F344 > SD > LE = Lewis.
|
|
|
|
Drug Discrimination. Baseline performance. As shown in Table 1, the number of sessions required until acquisition of the discrimination (sessions to criteria) varied across strains and training doses, with F344 requiring the fewest sessions and SD the most sessions (p < .05). There was no relationship, however, between the amount of training needed to acquire the discrimination and sensitivity to the discriminative stimulus effects of morphine. Table 1 also shows that there were no consistent differences across strains in the percentage of injection-appropriate responding engendered by the training dose of morphine or water. There were differences in response rate among the strains; in particular, LE rats responded at a higher rate than both F344 and Lewis groups under morphine and water training conditions (see Table 1).
Effects of opioids.
Fig. 4 shows
the effects of morphine, levorphanol, and buprenorphine in rats trained
to discriminate 3.0 (left) and 5.6 (right) mg/kg morphine from water.
Each of these opioids produced dose-dependent increases in the
percentage of drug-appropriate responding; this effect was observed in
all four strains of rats and in both training dose conditions. As shown
in Table 3, there were no consistent differences in sensitivity to the discriminative stimulus effects of
these opioids across these strains. Figure
5 shows the effects of butorphanol and
nalbuphine in rats trained to discriminate 3.0 (left) and 5.6 (right)
mg/kg morphine from water. Butorphanol and nalbuphine also produced
dose-dependent increases in the percentage of drug-appropriate
responding with no consistent differences in the potency of these drugs
or maximal effects across strains or training dose conditions (Table
3).
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
The present findings are consistent with a growing body of evidence indicating that the level of antinociception produced by a particular opioid is dependent on the intrinsic efficacy of the opioid and the nociceptive stimulus intensity. Furthermore, these findings demonstrate that F344, SD, LE, and Lewis rats differ in terms of the potency and effectiveness of various opioids. The magnitude of these differences is increased when tests are conducted using a relatively high-intensity nociceptive stimuli or lower-efficacy µ opioids. In contrast to the antinociceptive effects of µ opioids, a differential sensitivity (in either potency or maximal effects produced) across rat strains was not apparent in the drug discrimination procedure, regardless of the intrinsic efficacy of the opioid or the training dose of morphine.
One dimension along which µ opioids differ is their relative degree
of intrinsic efficacy at the µ opioid receptor. In antinociceptive assays, the relative efficacy of an opioid can often be inferred on the
basis of its effectiveness across different intensities of the
nociceptive stimulus (O'Callaghan and Holtzman, 1975
; Walker et al.,
1993
; Butelman et al., 1995
; Morgan and Picker, 1996
; Morgan et al.,
1999
). For example, whereas high-efficacy opioids typically produce
maximal antinociceptive effects regardless of the intensity of the
nociceptive stimulus, the potency and effectiveness of lower-efficacy
opioids typically decrease with increases in the intensity of the
nociceptive stimulus. Findings obtained in various assays indicate the
relative ranking of intrinsic efficacy for the µ opioids used in the
present study was: morphine
levorphanol > buprenorphine > butorphanol > nalbuphine (Adams et al.,
1990
; France and Woods, 1990
; Paronis and Holtzman, 1992
; Young et al., 1992
; Picker et al., 1993
). That the same ranking was obtained in the
present study in four strains of rats attests to the robustness of this
phenomenon. It should be noted that each of these drugs has significant
affinity for other types of opioid receptors (e.g.,
receptors);
however, studies from our laboratory and others using irreversible
and competitive antagonists and cross-tolerance regimens have
demonstrated that the antinociceptive effects of these drugs in this
procedure are primarily mediated by actions at the µ opioid receptor
(Zimmerman et al., 1987
; Walker et al., 1994
; Tiano et al., 1998
).
Furthermore, it has been demonstrated that when these opioids are
administered in combination they produce either additive effects or act
as competitive antagonists. Both of these outcomes are consistent with
activity at the same receptor site (probably the µ opioid receptor;
Morgan et al., 1999
).
A major goal of the present study was to evaluate the antinociceptive
effects of opioids in different rat strains and to determine if the
magnitude of the differences in sensitivity (in potency or maximal
effects) across rat strains is influenced by the sensitivity of the
task, which can be altered by changing the intensity of the nociceptive
stimulus. In general, the potency of the high-efficacy µ opioids
morphine and levorphanol to produce antinociception decreased with
increases in the intensity of the nociceptive stimulus. Differences in
the potency of these opioids across strains became apparent as the
intensity of the nociceptive stimulus increased. For example, morphine
was equipotent across strains at the low-intensity stimulus. At the
highest intensity however, morphine was approximately 2- and 3-fold
more potent in the F344 than in the SD and Lewis rats, respectively.
Most studies show little or no differences across rat strains in
response to morphine's antinociceptive effects (Woolfolk and Holtzman,
1995
), although consistent differences have been noted (Vaccarino and
Couret, 1995
). The present findings demonstrate that these differences
are most pronounced when high-intensity nociceptive stimuli are used.
Differences between the various strains of rats were also apparent when tested with opioids that have low efficacy at the µ opioid receptor. Both the potency and effectiveness of buprenorphine, butorphanol, and nalbuphine varied considerably across strains, with the F344 generally being the most sensitive and Lewis the least sensitive. The magnitude of this differential sensitivity was influenced by stimulus intensity. For example, although buprenorphine was approximately 18-fold more potent in the F344 when tested at 50°C water, maximal effects were obtained in both strains. In contrast, at the 56°C water, buprenorphine produced maximal effects in the F344 and was ineffective across the dose range examined in the Lewis. The most dramatic differences across strains were obtained with the lower-efficacy µ opioid butorphanol, where F344 rats showed maximal effects at a dose of 0.1 mg/kg and the Lewis failed to show any antinociceptive effects even when tested up to a dose as high as 56 mg/kg.
There are several possible explanations for the differential potency
and effectiveness across strains, including different pharmacokinetic
properties of these opioids (but see Guitart et al., 1992
; Gosnell and
Krahn, 1993
), differences in absolute numbers and/or densities of µ opioid receptors (Baran et al., 1975
; Sudakov et al., 1993
; Elmer et
al., 1995
), or different neurochemical attributes (e.g., endogenous
opioid levels; Beitner-Johnson et al., 1991
; Guitart et al., 1992
,
1993
; Strecker et al., 1995
). At this point, it is impossible to
conclude with certainty that any of these possibilities account for the
differential sensitivity observed in this study.
The findings that the antinociceptive effects of opioids were dependent
upon the stimulus intensity and the intrinsic efficacy of the opioid
suggest that the strain differences may reflect some fundamental
difference in the physiological mechanisms underlying efficacy. For
example, it is possible that the intracellular mechanisms determining µ opioid efficacy (e.g., the degree and/or the amount of G protein
activation; Selley et al., 1997
) differ across strains. That is, the
efficiency of the coupling mechanism between receptor and intracellular
signaling proteins in the F344 may be considerably greater than in the
Lewis. When tested with high-efficacy µ opioids, this difference may
not be apparent because these opioids require so few receptors to
produce maximal effects. Under conditions where the physiological
system is taxed (e.g., by increasing the intensity of the nociceptive
stimulus) or when using low-efficacy opioids that require occupation of
close to all available receptors to produce a given effect, these
intrinsic differences may result in measurable differences in potency
and/or effectiveness, as observed in the present study.
The findings obtained in the antinociception procedure contrast with
those obtained in the drug discrimination procedure where no consistent
differences across strains were observed. Several possibilities may
account for the lack of this differential sensitivity, including the
possibility that antinociceptive effects of these opioids are mediated
by different anatomical loci or pathways (e.g., the spinal cord) than
the discriminative stimulus and rate-decreasing effects (e.g., the
brain). A number of studies indicate that various spinal tracts and
neural structures, such as the periaqueductal gray, are important in
mediating opioid antinociception (for a review, see Yaksh, 1997
;
Jensen, 1997
). Although the neural correlates of the discriminative
stimulus or rate-decreasing effects of these opioids have not been
clearly identified, many of the substrates that mediate
opioid-induced antinociception have been eliminated (e.g., Jaeger and
van der Kooy, 1993
; Shoaib and Spanagel, 1994
).
An alternative explanation is that the drug discrimination
procedure is more sensitive to opioid agonist effects compared with
the tail withdrawal procedure (Holtzman, 1997
). In the drug discrimination procedure, the lower-efficacy opioids nalbuphine and
butorphanol produced maximal or near maximal effects in both the low
and high training dose conditions. In contrast, at the lowest water
temperature used in the tail withdrawal procedure, nalbuphine and
butorphanol produced no antinociception in the Lewis and only low
levels of effects in the F344. Furthermore, comparisons of
ED50 values suggest that these opioids were more potent in the drug discrimination procedure compared with the antinociception procedure. Taken together, these data suggest that the
drug discrimination procedure is more sensitive to agonist effects. It
is possible that differences between the strains would be more apparent
had higher training doses of morphine been used. Unfortunately,
higher doses of morphine (e.g., 10 mg/kg) eliminated responding in
both F344 and Lewis. A previous study (Young et al., 1992
) found that
nalbuphine failed to substitute for the same training dose of
morphine used in the present study. It has been previously
suggested (Picker et al., 1993
; Morgan and Picker, 1996
) that the
level of substitution observed with these opioids (i.e., lower-efficacy
opioids) across studies may vary substantially given the differences in
sensitivity across individuals. Whether the failure to directly
replicate Young et al.'s findings with nalbuphine are due to
individual differences or to procedural differences (e.g., route of
administration) is unclear at this point.
Taken together, the present findings suggest that there are particular situations where very profound differences in sensitivity to a drug effect exist between several strains of rats, and in some instances that these differences can be as large or larger than those observed in divergent lines of rodents selected for low- and high-sensitivity to a particular opioid effect. In particular, these differences are largest under extreme conditions (i.e., low-efficacy opioids or insensitive tasks are used).
| |
Acknowledgments |
|---|
We thank Michael Tiano and Jonas Horwitz for technical assistance.
| |
Footnotes |
|---|
Accepted for publication January 12, 1999.
Received for publication June 29, 1998.
1 This work was supported by National Institute on Drug Abuse Grant DA10277.
2 Supported by National Institute on Drug Abuse Predoctoral Fellowship DA05669. This manuscript partially fulfills the requirements for the Doctor of Philosophy Degree from the University of North Carolina at Chapel Hill. Present address: Department of Physiology and Pharmacology, Center for the Neurobiological Investigation of Drug Abuse, Wake Forest University School of Medicine, Medical Center Blvd., Winston-Salem, NC.
3 Supported by National Institute on Drug Abuse Training Grant DA07244.
Send reprint requests to: Mitchell J. Picker, University of North Carolina, Department of Psychology, CB#3270, Davie Hall, Chapel Hill, NC 27599-3270. E-mail: mjpicker{at}emailunc.edu
| |
Abbreviations |
|---|
LE, Long-Evans; FR, fixed ratio schedule; SD, Sprague-Dawley.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. Xie, J. H. Woods, J. R. Traynor, and M.-C. Ko The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies Anesth. Analg., June 1, 2008; 106(6): 1873 - 1881. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Haile and T. A. Kosten Differential Effects of D1- and D2-Like Compounds on Cocaine Self-Administration in Lewis and Fischer 344 Inbred Rats J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 509 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||